

SOLINTRA - INDUSTRY AND COMMERCE, LDA

It is an Angolan-registered company with the strategic objective of establishing partnerships with national or foreign entities that have their own capital or the ability to secure funding, either domestically or internationally, aimed at the construction and implementation of a **Pharmaceutical Complex in Angola.**



MAIN PRODUCTION LINES OF SOLINTRA

1 - PRODUCTION OF SALINE SOLUTIONS:

Manufacturing of parenteral solutions, with a focus on saline solutions for medical and hospital use.

2 - PRODUCTION OF TABLETS AND CAPSULES:

Development of solid oral medications, such as coated tablets and capsules, in compliance with international quality standards.



SALINE SOLUTIONS IN 100ML AND 500ML POLYPROPYLENE BOTTLES.

- Potential Production Capacity: 40 million units per year
- Medicines to be Produced: Sodium Chloride 0.9%,
 Glucose 5% and 10%, and Ringer's Lactate
- Investment Duration: 22 months
- Investment Cost: €33.1 million, according to the feasibility study
- Annual Sales: Up to €50 million, based on current market prices
- Payback Period: 48 months
- Loan Repayment: Starting from the fourth (4th) year of production



COATED TABLETS AND CAPSULES

- Potential production capacity: **875 million** tablets and capsules per year.
- Medicines to be produced: (44) including antimalarials, antihypertensives, analgesics, antidiabetics, anti-inflammatories, antiparasitics, etc.
- Investment duration: 22 months.
- Investment cost: €23.6 million.
- Annual sales: Up to €35.8 million, at current prices.
- Payback period: 21 months.
- Loan repayment: Starting from the fourth (4th) year of production.

BEHAVIOR OF ANNUAL REVENUES (PHYSIOLOGICAL SALINES)



| Indicators | U/M | Year 1 | Year 2 | Year 3 | Year 20 (Estimate) | TOTAL |
|----------------|-----|---------------|---------------|---------------|--------------------|----------------|
| National Sales | € | 15.952.950,00 | 31.905.900,00 | 35.894.137,50 | 35.894.137,50 | 681.988.612,50 |
| Export Sales | € | 0 | 12.565.800,00 | 14.136.525,00 | 14.136.525,00 | 252.886.725,00 |
| TOTALS | € | 15.952.950,00 | 44.471.700,00 | 50.030.662,50 | 50.030.662,50 | 934.875.337,50 |

BEHAVIOR OF ANNUAL REVENUES (TABLETS AND CAPSULES)



| Indicators | U/M | Year 1 | Year 2 | Year 3 | Year 20 (Estimate) | TOTAL |
|----------------|-----|---------------|---------------|---------------|--------------------|----------------|
| National Sales | € | 22.645.531,40 | 28.306.914,72 | 35.855.424,72 | 35.855.424,72 | 696.350.090,62 |
| Export Sales | € | 0 | 0 | 0 | 0 | 0 |
| TOTALS | € | 22.645.531,40 | 28.306.914,25 | 35.855.427,72 | 35.855.424,72 | 696.350.090,62 |

EFFICIENCY AND PROFITABILITY INDICATORS



| INDICATOR | SALINE SOLUTIONS | TABLETS | EVALUATION / INDICATOR (S.E.V |
|----------------|------------------|---------------|-------------------------------|
| NPV | 102.110.420,96 | 52.390.091,35 | Accepted |
| IRR | 48,31% | 70,35% | Accepted |
| B/C | 1,55 | 1,3 | Accepted |
| PAYBACK PERIOD | 48 months | 21 months | Accepted |



BENEFITS FOR THE PARTNERS AND FOR THE COUNTRY


- Generate revenues exceeding **80 million euros (€)** once production stabilizes (after the 3rd year).
- Ensure the production of physiological saline solutions to cover part of the **national demand.**
- Produce **antimalarial** and **antipaludic** medicines domestically and reduce imports in this category.
- Guarantee the production of other medicines that fight diseases such as hypertension, diabetes mellitus, tuberculosis, parasites, and other curable illnesses currently affecting the population's mortality.



- Create more than **250 jobs** during the investment process and **600 direct** and indirect jobs in the production process.
- Ensure the country's capacity to respond to outbreaks, pandemics, endemics, etc., without depending on the external market regarding these pharmacological groups.
- Link other productive sectors of the national economy with the pharmaceutical industry.
- Develop other pharmaceutical forms, such as injectables, syrups, suspensions, creams, etc., laying the foundation for sustained growth of the sector in the country.

CONTACT

We are available to build new opportunities together.





Thank you for your attention!